



**Empowering  
biologics  
delivery**

**Addressing the challenges  
of vaccine formulation**

**Excipients | Lipids | Adjuvant Systems**

# The building blocks for vaccine delivery systems

Combining our unique product portfolios and expertise, Croda Pharma and Avanti Polar Lipids are empowering the development and manufacturing of next generation vaccines. With strong expertise in high quality excipients, a culture of innovation and specialist scientific knowledge, we support our customers with the development of new and effective adjuvant systems and ingredients for vaccines.



We are passionately driving our innovation pipeline to expand our unique and comprehensive offer to our customers in both commercial and academic organisations worldwide.

Our world-class high purity excipients and lipids, together with the diverse portfolio of vaccine adjuvants and immunomodulators, provide a unique combination of building blocks to develop new adjuvant systems and vaccine delivery systems. Leveraging over 80 years of expertise, our scientists collaborate with vaccine developers and manufacturers to create solutions for vaccine formulation challenges.




# We put quality at the heart of everything we do

This commitment goes beyond products and consistency of the ingredient systems we bring to market. Our high standards encompass all levels of customer relationships. We provide customised advice and solutions and welcome partnerships across industry and research institutions.

This brochure provides insight into our offering for vaccine development across all platforms in Croda Pharma. Discover here how we can support you in the development of the next generation vaccines.


## Empowering biologics delivery




**Small Molecule Delivery**



**Protein Delivery**



**Nucleic Acid Delivery**



**Adjuvant Systems**

<b>Our journey to Croda Pharma.....</b>	<b>5</b>
<b>Offering for vaccines development.....</b>	<b>6</b>
<b>Dedicated production sites.....</b>	<b>7</b>
<b>Adjuvants.....</b>	<b>8</b>
Alhydrogel™.....	8
Adju-Phos™.....	8
PHAD™.....	9
3D-PHAD™.....	9
3D-(6-acyl)-PHAD™.....	9
QS-21.....	10
<b>Lipids for LNPs.....</b>	<b>11</b>
Phospholipids.....	11
Additional lipids.....	11
<b>Adjuvants development pipelines.....</b>	<b>12</b>
Cationic Adjuvant Formulation CAF®.....	12
NanoQuil™ technology.....	13
<b>Additional vaccine excipients.....</b>	<b>14</b>
Super Refined™ Polysorbate 20 and 80.....	15
Span™ 85 Pharma.....	16
Plant derived cholesterol.....	16
<b>Contact our experts.....</b>	<b>17</b>

# Our journey to Croda Pharma

Founded almost 100 years ago, Croda understands the central role science plays in our everyday lives. Today, that means using our Smart science to improve lives™.

Croda Pharma is at the forefront of pharmaceutical science, with the ability to deliver high quality excipients, quickly and at scale. The company has proven to be crucial for the rapid rollout of many COVID-19 vaccine programmes. Today we are a global, innovative, and application science-led business that positively impacts the health of millions of people.

Leveraging over 80 years of expertise in vaccine adjuvants development and manufacturing, Croda Pharma's industry-leading brands of aluminium-based adjuvants, Alhydrogel™ and Adju-Phos™, as well as the saponin-based Quil-A™ are widely recognised for their unmatched safety and effectiveness in both human and veterinary vaccines. This portfolio of essential products was acquired into the business along with an impressive GMP manufacturing site from Biosector in 2019, including sterile production and aseptic filling.

The year 2020 marked another important milestone in the evolution of the business. Avanti Polar Lipids, (Avanti) joined the Croda group. Founded in 1967, Avanti is a global leader in the manufacture and supply of the highest purity lipids for research and pharmaceutical product development. Avanti revolutionised vaccine development with the introduction of synthetic monophosphoryl lipid (MPL) A derivatives.

And now, it manufactures multiple synthetic analogues of MPL containing a single molecular species. These are as effective and safe at inducing an immune response as their natural product predecessor.

Over the past decade, Avanti has concentrated on developing high purity lipids for liposomal delivery systems including Lipid Nanoparticle (LNP). LNP delivery technology helps solve the stability and delivery issues associated with mRNA-based vaccines and therapeutics, as well as gene editing technology.

Driven by sustainability, innovation, and our portfolio of market-leading products, Croda Pharma, much like the whole Croda organisation, is committed to having a positive impact on the environment and society.

Alongside our partners, we continue to develop adjuvants to target new diseases and pathogens such as cancer, Alzheimer's, malaria, tuberculosis, HIV, *Staphylococcus aureus*, amongst others.

**We are committed to the United Nations Sustainable Development Goals (SDGs). By the end of 2030, our technology will be part of at least 10 clinical phase III trials across at least 25% of the WHO-listed pipeline vaccines.**



# Offering for vaccines development

## Enabling breakthrough innovation

Our vaccine adjuvant portfolio is founded on strong research and development. We recognise the need for new and efficacious adjuvant systems to fight diseases by prophylactic and therapeutic vaccines. Therefore, we develop new adjuvant systems and welcome partnerships who share our passion to create the vaccines of tomorrow.

## A unique blend of support and expertise

Our combined experience is based on decades of formulation knowledge with pharmaceutical excipients, lipid-based formulations, and aluminium- and saponin-based adjuvants. We make use of our entire knowledge to ensure quality and consistency to make your project successful.

## A focus on scientific endeavour

We are committed to enabling next generation drug delivery systems. Leveraging innovation, formulation and application, we are determined to deliver better excipients, lipids and adjuvants systems for biopharma, to unlock more treatments.

## R&D is our foundation

With our leading R&D capabilities, we are advancing our strong pipeline of innovative next generation adjuvants, lipids and high purity excipients.

We recognise that only an R&D focus will allow us to develop the new, innovative vaccine adjuvants that are required to deal with challenging infectious diseases and pathogens.



# Dedicated production sites

Our production site located in Denmark has been dedicated to safe and effective adjuvants for use in human and veterinary vaccines for more than 80 years. Our expertise in this area is simply unmatched. We support the major human and veterinary vaccine producers through an experienced team operating the only cGMP certified manufacturing site including aseptic filling globally, for aluminium-based adjuvants.

Another major production site is located in Alabama, USA. With decades of combined experience in formulating lipids, the teams there support vaccine formulation and development activities. Further, formulation services for both pre-clinical and clinical development using our own cGMP manufactured lipids are offered. Batches can be scaled from a few millilitres to >100 litres to accommodate your stage of clinical development.

Across our other facilities for vaccine components, we work in partnership with our customers to provide a seamless transfer of the formulation for scale-up and manufacturing.



# Adjuvants

## Alhydrogel™

**Alhydrogel** is a range of aluminium hydroxide gels specifically developed for use as adjuvants in human and veterinary vaccines.


Alhydrogel has very low conductivity due to the absence of buffering ions and is positively charged at neutral pH. This allows the product to effectively adsorb negatively charged antigens.

Alhydrogel products can be combined with other adjuvant types (such as monophosphoryl lipids) to achieve a well-balanced Th1/Th2 immune response.

Alhydrogel is supplied in two concentrations:

Alhydrogel 1.3% and Alhydrogel 2%. A premium version (Alhydrogel "85") with higher protein adsorption capacity is also available.

The range is manufactured according to EU GMP (Part I: Medicinal Products for Human and Veterinary Use) certified production of aseptically prepared sterile products.



Alhydrogel is a registered trademark of Croda International Plc.



## Adju-Phos™

**Adju-Phos** is a range of aluminium phosphate gel products specifically developed for use as adjuvants in vaccines.

Adju-Phos products have a net negative charge at neutral pH and effectively adsorb positively charged antigens.

Like Alhydrogel, Adju-Phos products can be combined with other adjuvant types (such as monophosphoryl lipids) to achieve a well-balanced Th1/Th2 immune response.

It is supplied with two variants of pH-values to reduce injection site discomfort.

Adju-Phos is manufactured according to EU GMP (Part I: Medicinal Products for Human and Veterinary Use) certified production of aseptically prepared sterile products.

**Adju-Phos is a registered trademark of Croda International Plc.**


## PHAD™

**PHAD**, Phosphorylated HexaAcyl Disaccharide, is the first synthetic equivalent to bacterial-derived monophosphoryl lipid A (MPLA) used as an adjuvant in vaccines.

It boosts the immune system through activation of the toll-like receptor 4 (TLR4) resulting in production of proinflammatory cytokines and antigen-specific effector CD4+ and memory CD8+ T-cells.

Also referred to as GLA, PHAD, has been administered to over a thousand human subjects without serious adverse events.

PHAD is available in bulk quantities for vaccine development and commercial manufacturing.



## 3D-PHAD™

A highly pure PHAD, 3D-PHAD provides a homogeneous synthetic equivalent for the 3-deacylated MPLA derived from bacterial LPS (lipopolysaccharides).

Less pyrogenic than its bacterial-derived mimic, it is comparable to bacterial MPLA and other synthetic MPLA analogues at eliciting an immune response in a liposomal adjuvant system.

The product has demonstrated equivalency to PHAD during extensive preclinical testing, and human trials are scheduled for launch.

3D-PHAD is protected under US Pat No. 9,241,988. Licensing opportunities are available for vaccine or immunotherapy commercialisation.

## 3D-(6-acyl)-PHAD™

A synthetic MPLA structural analogue, 3D-(6-acyl)-PHAD is most closely related to the reported structure of MPL® Adjuvant used in marketed liposomal adjuvant systems.

This adjuvant is structurally homogeneous and highly purified. It mimics the TLR4 agonist activity of bacterial MPLA.

PHAD, 3D-PHAD, and 3D-(6-acyl)-PHAD have been tested extensively in animals using a variety of antigens. In all cases, these adjuvants exhibit a similar activity and safety profile to bacterially derived MPL.

**PHAD is a registered trademark of  
Avanti Polar Lipids Inc.**

# Adjuvants

## QS-21

QS-21 is a water-soluble purified triterpenoid saponin molecule fraction from the bark of the South American tree *Quillaja saponaria Molina*. It is an amphiphilic surfactant and the most widely used saponin adjuvant.

Having been used in veterinary vaccines since the 1970s, it has demonstrated optimal balance of enhanced immunostimulatory properties and tolerable reactogenicity.

Human vaccines containing QS-21 are now commercially available and used to prevent diseases such as malaria. Before this development, it was not possible to develop effective vaccines against malaria.

Croda's QS-21 is a highly purified saponin-derived immunologic adjuvant obtained by successive chromatographic purification cycles.

It is derived from Quil-A which has been manufactured by Croda since 1982. A special fraction of Quil-A – the so-called QS-21 – has found its way into human applications.



Croda's QS-21 is manufactured according to GMP requirements for Investigational Medicinal Product of the EU and is intended "for investigational use only". It is supplied as a lyophilised product in 5 mg vials and dispatched frozen.

# Lipids for LNPs

Lipid Nanoparticles (LNPs) have been shown to be effective at delivering mRNA vaccines. Traditionally, LNP systems include four lipid components: Cationic lipid, PEG lipid, structural/neutral lipid, and cholesterol.

The ionisable cationic lipid sequesters the genetic material through a charge interaction and releases the material following a pH change in the endosome. The PEG lipid component forms the exterior shell to protect the LNP and decreases particle aggregation.

The structural/neutral lipid stabilises the LNP and can prevent premature breakdown. Finally, cholesterol acts as a stability enhancer and assists in the transfection of RNA.

**Explore some of the lipids from our GMP portfolio.**


## Phospholipids:

- DSPC
- DMPC
- DOPC
- DMPG

## Additional lipids:

- ALC-0315
- ALC-0159

Further research grade materials are available through the Avanti website [www.avantilipids.com](http://www.avantilipids.com)



# Adjuvants development pipelines

## Cationic Adjuvant Formulation CAF®

A common challenge for adjuvants is that they significantly increase the humoral response to vaccine antigens but induce only very weak cell-mediated immunity (CMI) responses. There is therefore a need for designing vaccine adjuvants that prime T-cell immunity, for effective vaccines against many intracellular pathogens.


Croda Pharma continuously increases its offering in innovative vaccine adjuvant systems. The strategic collaboration with SSI (Statens Serum Institut, leading Danish governmental life-science research institute) enables us to offer an even more diverse adjuvant portfolio.

The CAF technology platform is a range of new, patented, CMI inducing cationic liposomal adjuvants. Over the past decade, clinical trials have shown these to be powerful immunostimulators in tuberculosis, chlamydia, HIV, malaria, pandemic flu and specific cancer studies.

Croda will manufacture and commercialise two CAF adjuvants:


- **CAF01** – a two component liposomal suspension which induces strong antibody and T-cell (Th1/Th17) responses in vaccines for infectious diseases. The potent neonatal adjuvanticity in preclinical studies suggests that it is fulfilling the requirements for novel vaccines to be used in early life.
- **CAF09b** – a second generation, three component cationic liposomal adjuvant used in cancer immunotherapy trials, facilitating strong production of antigen specific CD8 + T-cells after vaccination in combination with peptide or protein-based antigens.

CAF01 induces systemic immunity, facilitating mucosal booster responses after mucosal administration of antigens alone. Preclinical studies indicate CAF09b could be a potent adjuvant for mucosal applications directly priming the immune response.



## NanoQuil™ technology

Saponin-based immunostimulating nanoparticles have potential for use in vaccinology. We are working on development and commercialisation of new generation saponin-based nanoparticles within the NanoQuil range.



Saponins from the bark of *Quillaja saponaria Molina* show a potent activation of dendritic cells and induction of cytokines/chemokines resulting in a strong stimulation of cell-mediated (Th1) and antibody-mediated (Th2) immune response.

However, saponins are prone to hydrolysis and degradation at physiological pH at ambient temperatures. In addition, cell-lytic properties lead to local reactions at the injection site. This requires a balanced adjuvant dose between the immunostimulatory effect and the local reaction.

NanoQuil technology has been developed to overcome the challenges of saponins while securing the benefits. It consists of a series of immunostimulating nanoparticles developed for use in both veterinary and human applications.

NanoQuil is based on incorporation of saponin in cholesterol resulting in increasing stability of saponins and reducing negative cell-lytic effect due to its low reactogenicity.

# Additional vaccine excipients

Croda offers a comprehensive range of high quality pharmaceutical components. We continuously expand the range in response to market needs.

All our components are designed and manufactured for pharmaceutical use, using Good Manufacturing Practice (GMP) standards across all our platforms and manufacturing sites. We were one of the first excipient suppliers to receive EXCiPACT® certifications across all our global sites and continue to pioneer new monograph approvals via our representation on global monograph industry forums.

We believe that having the highest quality and purest grades of components helps our customers formulate seamlessly and drive products to market quickly and efficiently.

Croda's Super Refined™ range of highly purified excipients is manufactured through proprietary processes that remove impurities without affecting the fundamental structure in any way.

**Super Refined is a registered trademark of Croda International Plc.**



## Super Refined™ Polysorbate 20 and 80

It is widely reported in the scientific community that polysorbates can prevent proteins from denaturation, aggregation, surface adsorption and flocculant formulation during product thawing. They are also used in downstream and upstream processes as detergents, washing agents, splitting agents, blocking agents and for lysing cells.

Commonly found impurities in standard compendial grade excipients can negatively influence formulations. Several types of surfactants oxidise readily when exposed to the air or UV light, causing them to lose their properties and potency as solubilising agents. Purity is an incredibly important factor for successful vaccine development.

Polysorbate 20 and 80 (Tween™ 20 and Tween 80) are non-ionic surfactants which are widely used as

excipients in the pharma industry; from oral, topical, and injectable applications to blood fractionating, vaccine development and formulation.

Super Refined Polysorbates have been developed to optimise the performance of pharmaceutical formulations and are recommended when the highest quality and purity is required. The level of impurities which are known to have an adverse effect on formulation stability has been reduced.

Super Refined Polysorbate 20 and 80 are manufactured according to GMP standards in EXCiPACT certified factories and comply with USP/NF, Ph. Eur., JP and ChP. Chinese DMFs are filed at CDE including for parenteral use.

**Tween is a registered trademark of Croda International Plc.**





## Span™ 85 Pharma

Span 85 is a non-ionic low HLB surfactant widely used as dispersant, solubiliser, suspending and wetting agent. It is used in MF59 adjuvant system, together with squalene and Polysorbate 80. It is the first o/w adjuvant approved for human influenza vaccines and under clinical evaluation for HIV and CMV.

Croda's Span 85 Pharma complies with Ph. Eur. and is manufactured according to GMP standards in the EXCiPACT certified factories.

**Span is a registered trademark of  
Croda International Plc.**

## Plant derived cholesterol

Cholesterol is an essential ingredient in a wide range of technologies from adjuvants systems, lipid nanoparticles for mRNA delivery to cell culture media. In the last few years, there has been increasing demand for cholesterol from a plant-based source.

Our plant-based and parental grade cholesterol provides a high-purity alternative to traditional egg and animal-based cholesterol and is USP/NF, JP and parenteral grade Ph. Eur. compliant.



# Contact our experts

**Croda Pharma partners with world leading pharmaceutical organisations to solve the most complex health and well-being challenges our society faces in this millennium.**

We support the entire biologics development lifecycle through local support and worldwide manufacturing capabilities, helping to bring new vaccines and biologic therapies to market faster and at scale.

We engage with customers through our global network of Croda employees around the world and welcome close cooperation to develop the products of tomorrow.

To discuss your needs or for any further product information, such as monograph compliance, please contact your sales representative or email us at:

**Europe, Middle East & Africa:**

[pharma.emea@croda.com](mailto:pharma.emea@croda.com)

**North America:**

[pharma.usa@croda.com](mailto:pharma.usa@croda.com)

**Latin America:**

[pharma.latam@croda.com](mailto:pharma.latam@croda.com)

**Asia Pacific:**

[pharma.asia@croda.com](mailto:pharma.asia@croda.com)



Scan below to visit our websites:



Croda Pharma



Avanti Polar Lipids



#### Non-warranty

The information in this publication is believed to be accurate and is given in good faith, but no representation or warranty as to its completeness or accuracy is made. Suggestions for uses or applications are only opinions. Users are responsible for determining the suitability of these products for their own particular purpose. No representation or warranty, expressed or implied, is made with respect to information or products including, without limitation, warranties of merchantability, fitness for a particular purpose, non-infringement of any third-party patent or other intellectual property rights including, without limit, copyright, trademark and designs. Unless otherwise stated, any trademarks identified herein are trademarks of the Croda group of companies.

©2022 Croda International.

10/22 HTCMB051v1 EN